



Clinical trial results:

A Phase III, observer-blind, randomized, multi-country study to evaluate the lot-to-lot consistency of GSK's investigational RSV maternal vaccine and the immune response, safety and reactogenicity of RSV maternal vaccine when co-administered with GSK's quadrivalent influenza D-QIV vaccine in healthy non-pregnant women 18-49 years of age.

Summary

EudraCT number	2021-000357-26
Trial protocol	ES FI
Global end of trial date	06 June 2022

Results information

Result version number	v2 (current)
This version publication date	14 December 2023
First version publication date	18 June 2023
Version creation reason	• Correction of full data set Corrections made on Group definitions.

Trial information

Trial identification

Sponsor protocol code	214709
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	GSK Response Center, GlaxoSmithKline, 44 8664357343, GSKClinicalSupportHD@gsk.com
Scientific contact	GSK Response Center, GlaxoSmithKline, 44 8664357343, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	11 November 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	06 June 2022
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the safety and reactogenicity of RSV MAT vaccine when given alone (pooled lots) or co-administered with Flu D-QIV vaccine up to study end.

- To demonstrate the lot-to-lot consistency of 3 lots of the investigational RSV MAT vaccine based on Geometric mean concentration (GMC) of RSV MAT IgG ELISA at Day 31.
- To demonstrate non-inferiority of Flu D-QIV vaccine when co-administered with RSV MAT vaccine compared to Flu D-QIV vaccine given alone based on Geometric mean titer (GMT) of Flu D-QIV antibody titers against 3 influenza strains at Day 31 post administration.

Protection of trial subjects:

Study participants were observed closely for at least 30 minutes after the administration of the study intervention(s). Appropriate medical treatment was readily available during the observation period.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	15 September 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 451
Country: Number of subjects enrolled	Finland: 113
Country: Number of subjects enrolled	Korea, Republic of: 117
Country: Number of subjects enrolled	Spain: 584
Country: Number of subjects enrolled	United States: 321
Worldwide total number of subjects	1586
EEA total number of subjects	697

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	1586
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Out of 1586 participants enrolled, 47 participants did not receive vaccination as they did not meet the eligibility criteria or they were lost to follow up, therefore only 1539 participants were included in the Exposed Set and started the study.

Pre-assignment

Screening details:

As pre-specified in statistical plan, data reported were presented for individual RSV lot groups, pooled RSV+Flu group and Flu+Placebo Group. As pre-specified in protocol, immunogenicity outcome measures presented data for the pooled groups, and individual RSV lot groups were used for lot-to-lot analyses.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Single blind
Roles blinded	Investigator ^[1]

Arms

Are arms mutually exclusive?	Yes
Arm title	RSV lot1 Group

Arm description:

Participants randomized to the RSV lot1 Group received one dose of RSV MAT Lot 1 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.

Arm type	Experimental
Investigational medicinal product name	RSVPreF3(120 µg)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solution for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

A single dose of RSVPreF3(120 µg) combined with Sodium Chloride (NaCl) was administrated intramuscular (IM). There were used 3 different lots of RSVPreF3(120 µg), one for each individual group (RSV lot1 Group, RSV lot2 Group and RSV lot3 Group) considered under RSV pooled Group.

Arm title	RSV lot2 Group
------------------	----------------

Arm description:

Participants randomized to the RSV lot2 Group received one dose of RSV MAT Lot 2 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.

Arm type	Experimental
Investigational medicinal product name	RSVPreF3(120 µg)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solution for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

A single dose of RSVPreF3(120 µg) combined with Sodium Chloride (NaCl) was administrated intramuscular (IM). There were used 3 different lots of RSVPreF3(120 µg), one for each individual group (RSV lot1 Group, RSV lot2 Group and RSV lot3 Group) considered under RSV pooled Group.

Arm title	RSV lot3 Group
------------------	----------------

Arm description:

Participants randomized to the RSV lot3 Group received one dose of RSV MAT Lot 3 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.

Arm type	Experimental
Investigational medicinal product name	RSVPreF3(120µg)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solution for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

A single dose of RSVPreF3(120µg) combined with Sodium Chloride (NaCl) was administrated intramuscular (IM). There were used 3 different lots of RSVPreF3(120µg), one for each individual group (RSV lot1 Group, RSVlot2 Group and RSV lot3 Group) considered under RSV pooled Group.

Arm title	RSV+Flu pooled Group
------------------	----------------------

Arm description:

Participants randomized in this group received one dose of RSVPreF3 vaccine (RSV MAT vaccine) from one of the three lots used (Lot 1, Lot 2 or Lot 3 of same formulation of RSVPreF3 vaccine) and one dose of the Flu D-QIV vaccine on Day 1, and were followed up until the end of the study (Day 181). The participants in this group were considered for the immunogenicity and safety analyses of the RSV MAT and Flu D-QIV vaccines.

Arm type	Experimental
Investigational medicinal product name	RSVPreF3(120µg)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solution for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

A single dose of RSVPreF3 (120µg) combined with Sodium Chloride (NaCl) was administrated intramuscular (IM). There were used 3 different lots of RSVPreF3 (120µg), one for each individual group (RSV lot1 Group, RSVlot2 Group and RSV lot3 Group) considered under RSV pooled Group.

Investigational medicinal product name	Flu Quadrivalent influenza vaccine (15 µg HA)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

A single dose of Flu Quadrivalent influenza (15 µg HA) vaccine was administrated intramuscular (IM).

Arm title	Flu+Placebo Group
------------------	-------------------

Arm description:

Participants randomized in this group received one dose of Flu D-QIV vaccine co-administered with one dose of placebo at Day 1, and were followed up until the end of the study (Day 181). This group was considered comparator for immunogenicity and safety analyses for RSV+ Flu Pooled group.

Arm type	Experimental
Investigational medicinal product name	Flu Quadrivalent influenza vaccine (15 µg HA)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

A single dose of Flu Quadrivalent influenza (15 µg HA) vaccine was administrated intramuscular (IM).

Notes:

[1] - The roles blinded appear inconsistent with a simple blinded trial.

Justification: This study had the purpose to evaluate the lot-to-lot consistency of RSVPreF3 vaccine and the immune response, reactogenicity and safety of the RSVPreF3 vaccine when coadministered with Flu

D-QIV vaccine, thus the study is a single blinded trial.

Number of subjects in period 1^[2]	RSV lot1 Group	RSV lot2 Group	RSV lot3 Group
Started	220	223	218
Completed	217	220	214
Not completed	3	3	4
Consent withdrawn by subject	-	1	-
MIGRATED / MOVED FROM THE STUDY AREA	-	-	1
Lost to follow-up	3	2	3

Number of subjects in period 1^[2]	RSV+Flu pooled Group	Flu+Placebo Group
Started	438	440
Completed	433	427
Not completed	5	13
Consent withdrawn by subject	-	-
MIGRATED / MOVED FROM THE STUDY AREA	-	-
Lost to follow-up	5	13

Notes:

[2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: In this study, only the eligible participants from the worldwide total received the study intervention and started the study, hence the difference between the worldwide number enrolled in the trial and the baseline period number of participants.

Baseline characteristics

Reporting groups

Reporting group title	RSV lot1 Group
Reporting group description:	
Participants randomized to the RSV lot1 Group received one dose of RSV MAT Lot 1 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.	
Reporting group title	RSV lot2 Group
Reporting group description:	
Participants randomized to the RSV lot2 Group received one dose of RSV MAT Lot 2 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.	
Reporting group title	RSV lot3 Group
Reporting group description:	
Participants randomized to the RSV lot3 Group received one dose of RSV MAT Lot 3 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.	
Reporting group title	RSV+Flu pooled Group
Reporting group description:	
Participants randomized in this group received one dose of RSVPreF3 vaccine (RSV MAT vaccine) from one of the three lots used (Lot 1, Lot 2 or Lot 3 of same formulation of RSVPreF3 vaccine) and one dose of the Flu D-QIV vaccine on Day 1, and were followed up until the end of the study (Day 181). The participants in this group were considered for the immunogenicity and safety analyses of the RSV MAT and Flu D-QIV vaccines.	
Reporting group title	Flu+Placebo Group
Reporting group description:	
Participants randomized in this group received one dose of Flu D-QIV vaccine co-administered with one dose of placebo at Day 1, and were followed up until the end of the study (Day 181). This group was considered comparator for immunogenicity and safety analyses for RSV+ Flu Pooled group.	

Reporting group values	RSV lot1 Group	RSV lot2 Group	RSV lot3 Group
Number of subjects	220	223	218
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	220	223	218
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous			
Units: years			
median	32.0	31.4	31.9
standard deviation	± 9.6	± 9.4	± 9.3
Sex: Female, Male			
Units: Participants			
Female	220	223	218

Male	0	0	0
------	---	---	---

Race/Ethnicity, Customized Units: Subjects			
AMERICAN INDIAN OR ALASKA NATIVE	2	4	3
ASIAN	22	25	21
BLACK OR AFRICAN AMERICAN	12	3	6
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	0	0	0
OTHER	1	4	3
WHITE	183	187	185

Reporting group values	RSV+Flu pooled Group	Flu+Placebo Group	Total
Number of subjects	438	440	1539
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	438	440	1539
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous Units: years			
median	32.0	32.1	-
standard deviation	± 8.9	± 8.9	-
Sex: Female, Male Units: Participants			
Female	438	440	1539
Male	0	0	0
Race/Ethnicity, Customized Units: Subjects			
AMERICAN INDIAN OR ALASKA NATIVE	10	7	26
ASIAN	38	43	149
BLACK OR AFRICAN AMERICAN	17	17	55
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	1	0	1
OTHER	3	7	18
WHITE	369	366	1290

Subject analysis sets

Subject analysis set title	RSV pooled Group
Subject analysis set type	Per protocol

Subject analysis set description:

The RSV pooled Group consisted of participants pooled from RSV lot1, RSV lot2 and RSV lot3 groups. This pooled group was considered for the immunogenicity analysis of the RSV MAT vaccine.

Reporting group values	RSV pooled Group		
Number of subjects	661		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	661		
From 65-84 years	0		
85 years and over	0		
Age continuous			
Units: years			
median			
standard deviation	±		
Sex: Female, Male			
Units: Participants			
Female	661		
Male	0		
Race/Ethnicity, Customized			
Units: Subjects			
AMERICAN INDIAN OR ALASKA NATIVE	9		
ASIAN	68		
BLACK OR AFRICAN AMERICAN	21		
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	0		
OTHER	8		
WHITE	555		

End points

End points reporting groups

Reporting group title	RSV lot1 Group
Reporting group description: Participants randomized to the RSV lot1 Group received one dose of RSV MAT Lot 1 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.	
Reporting group title	RSV lot2 Group
Reporting group description: Participants randomized to the RSV lot2 Group received one dose of RSV MAT Lot 2 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.	
Reporting group title	RSV lot3 Group
Reporting group description: Participants randomized to the RSV lot3 Group received one dose of RSV MAT Lot 3 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.	
Reporting group title	RSV+Flu pooled Group
Reporting group description: Participants randomized in this group received one dose of RSVPreF3 vaccine (RSV MAT vaccine) from one of the three lots used (Lot 1, Lot 2 or Lot 3 of same formulation of RSVPreF3 vaccine) and one dose of the Flu D-QIV vaccine on Day 1, and were followed up until the end of the study (Day 181). The participants in this group were considered for the immunogenicity and safety analyses of the RSV MAT and Flu D-QIV vaccines.	
Reporting group title	Flu+Placebo Group
Reporting group description: Participants randomized in this group received one dose of Flu D-QIV vaccine co-administered with one dose of placebo at Day 1, and were followed up until the end of the study (Day 181). This group was considered comparator for immunogenicity and safety analyses for RSV+ Flu Pooled group.	
Subject analysis set title	RSV pooled Group
Subject analysis set type	Per protocol
Subject analysis set description: The RSV pooled Group consisted of participants pooled from RSV lot1, RSV lot2 and RSV lot3 groups. This pooled group was considered for the immunogenicity analysis of the RSV MAT vaccine.	

Primary: Percentage of participants reporting solicited administration site events in RSV pooled Group, RSV+Flu pooled Group and Flu+Placebo Group

End point title	Percentage of participants reporting solicited administration site events in RSV pooled Group, RSV+Flu pooled Group and Flu+Placebo Group ^{[1][2]}
End point description: Assessed solicited administration site events include pain, erythema and swelling. This objective analyzed the safety and reactogenicity of RSV MAT vaccine when given alone (pooled lots) or co-administered with Flu D-QIV. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled RSV and RSV+Flu groups and Flu+Placebo Group, since minimal differences were expected between participants who received different RSV lots of the vaccine. Analysis was performed on the Solicited Safety Set (SSS), which includes all participants who received at least 1 dose of the study intervention (Exposed Set [ES]) and who have solicited safety data.	
End point type	Primary
End point timeframe: From Day 1 to Day 7 (including Day 7)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical analysis was presented.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was descriptive, hence no statistical analysis was presented.

End point values	RSV+Flu pooled Group	Flu+Placebo Group	RSV pooled Group	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	438	439	660	
Units: Percentage of participants				
number (confidence interval 95%)				
Pain	51.1 (46.4 to 55.9)	34.4 (30 to 39)	53.6 (49.7 to 57.5)	
Erythema	3.7 (2.1 to 5.9)	0.5 (0.1 to 1.6)	4.4 (3 to 6.2)	
Swelling	4.6 (2.8 to 7)	0.9 (0.2 to 2.3)	4.5 (3.1 to 6.4)	

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of participants reporting solicited systemic events in RSV pooled Group, RSV+Flu pooled Group and Flu+Placebo Group

End point title	Percentage of participants reporting solicited systemic events in RSV pooled Group, RSV+Flu pooled Group and Flu+Placebo Group ^{[3][4]}
-----------------	--

End point description:

Assessed solicited systemic events include fatigue, headache, gastrointestinal (GI) symptoms (nausea, vomiting, diarrhea, abdominal pain) and fever. The preferred location for measuring temperature was the oral cavity. Fever was defined as temperature equal to or above (\geq) 38.0 °C/ 100.4°F. This objective analyzed the safety and reactogenicity of RSV MAT vaccine when given alone (pooled lots) or co-administered with Flu D-QIV. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled RSV and RSV+Flu groups and Flu+Placebo Group, since minimal differences were expected between participants who received different RSV lots of the vaccine. Analysis was performed on the Solicited Safety Set (SSS), which includes all participants who received at least 1 dose of the study intervention (Exposed Set [ES]) and who have solicited safety data.

End point type	Primary
----------------	---------

End point timeframe:

From Day 1 to Day 7 (including Day 7)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical analysis was presented.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis was presented.

End point values	RSV+Flu pooled Group	Flu+Placebo Group	RSV pooled Group	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	438	439	660	
Units: Percentage of participants				
number (confidence interval 95%)				
Fatigue	59.8 (55.1 to 64.4)	51.9 (47.1 to 56.7)	52 (48.1 to 55.8)	
Headache	51.4 (46.6 to 56.1)	43.1 (38.4 to 47.8)	47.6 (43.7 to 51.5)	

Nausea	15.3 (12.1 to 19)	12.3 (9.4 to 15.7)	14.5 (11.9 to 17.5)	
Vomiting	1.8 (0.8 to 3.6)	2.3 (1.1 to 4.1)	2.3 (1.3 to 3.7)	
Diarrhea	13 (10 to 16.5)	17.1 (13.7 to 20.9)	12.1 (9.7 to 14.9)	
Abdominal pain	13.5 (10.4 to 17)	14.1 (11 to 17.7)	12 (9.6 to 14.7)	
Temperature	3 (1.6 to 5)	0.7 (0.1 to 2)	2.4 (1.4 to 3.9)	

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of participants reporting unsolicited adverse events (AEs) in RSV pooled Group, RSV+Flu pooled Group and Flu+Placebo Group

End point title	Percentage of participants reporting unsolicited adverse events (AEs) in RSV pooled Group, RSV+Flu pooled Group and Flu+Placebo Group ^{[5][6]}
-----------------	---

End point description:

An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event. This objective analyzed the safety and reactogenicity of RSV MAT vaccine when given alone (pooled lots) or co-administered with Flu D-QIV. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled RSV and RSV+Flu groups and Flu+Placebo Group, since minimal differences were expected between participants who received different RSV lots of the vaccine.

Analysis was performed on the ES (Exposed Set), which includes all participants who received at least 1 dose of the study treatment.

End point type	Primary
----------------	---------

End point timeframe:

From Day 1 to Day 30 (including Day 30)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical analysis was presented.

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis was presented.

End point values	RSV+Flu pooled Group	Flu+Placebo Group	RSV pooled Group	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	438	440	661	
Units: Percentage of participants				
number (confidence interval 95%)	30.1 (25.9 to 34.7)	25.7 (21.7 to 30)	26.6 (23.3 to 30.2)	

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of participants reporting serious adverse events (SAEs) in RSV

pooled Group, RSV+Flu pooled Group and Flu+Placebo Group

End point title	Percentage of participants reporting serious adverse events (SAEs) in RSV pooled Group, RSV+Flu pooled Group and Flu+Placebo Group ^{[7][8]}
-----------------	--

End point description:

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or results in abnormal pregnancy outcomes. This objective analyzed the safety and reactogenicity of RSV MAT vaccine when given alone (pooled lots) or co-administered with Flu D-QIV. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled RSV and RSV+Flu groups and Flu+Placebo Group, since minimal differences were expected between participants who received different RSV lots of the vaccine. Analysis was performed on the ES, which includes all participants who received at least 1 dose of the study treatment.

End point type	Primary
----------------	---------

End point timeframe:

From Day 1 to Day 30 (including Day 30)

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical analysis was presented.

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis was presented.

End point values	RSV+Flu pooled Group	Flu+Placebo Group	RSV pooled Group	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	438	440	661	
Units: Percentage of participants				
number (confidence interval 95%)	0 (0 to 0.8)	0.2 (0 to 1.3)	0.2 (0 to 0.8)	

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of participants reporting SAEs in RSV pooled Group, RSV+Flu pooled Group and Flu+Placebo Group

End point title	Percentage of participants reporting SAEs in RSV pooled Group, RSV+Flu pooled Group and Flu+Placebo Group ^{[9][10]}
-----------------	--

End point description:

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or results in abnormal pregnancy outcomes. This objective analyzed the safety and reactogenicity of RSV MAT vaccine when given alone (pooled lots) or co-administered with Flu D-QIV. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled RSV and RSV+Flu groups and Flu+Placebo Group, since minimal differences were expected between participants who received different RSV lots of the vaccine. Analysis was performed on the ES, which includes all participants who received at least 1 dose of the study treatment.

End point type	Primary
----------------	---------

End point timeframe:

From first vaccination up to study end (Day 1 to Day 181)

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical analysis was presented.

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis was presented.

End point values	RSV+Flu pooled Group	Flu+Placebo Group	RSV pooled Group	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	438	440	661	
Units: Percentage of participants				
number (confidence interval 95%)	0.9 (0.2 to 2.3)	0.9 (0.2 to 2.3)	0.8 (0.2 to 1.8)	

Statistical analyses

No statistical analyses for this end point

Primary: RSV MAT immunoglobulin G (IgG) Enzyme-Linked Immunosorbent Assay (ELISA) concentrations for participants in RSV lot1, RSV lot2 and RSV lot3 groups at Day 31

End point title	RSV MAT immunoglobulin G (IgG) Enzyme-Linked Immunosorbent Assay (ELISA) concentrations for participants in RSV lot1, RSV lot2 and RSV lot3 groups at Day 31 ^[11]
-----------------	--

End point description:

Serological assays for the determination of IgG antibodies against RSV MAT were performed by ELISA. RSV MAT IgG concentrations were expressed as geometric mean concentrations (GMCs), in ELISA units per milliliter (EU/mL). As pre-specified in protocol, data reported in this outcome measure was presented only for individual RSV lot groups (RSV lot1, RSV lot2, RSV lot3), as the purpose was to analyze RSV MAT IgG ELISA concentrations, in order to demonstrate the lot-to-lot consistency of the vaccine lots.

Analysis was performed on the Per Protocol Set (PPS), only on the participants who received only 1 dose of RSV MAT vaccine (from RSV MAT vaccine Lot 1, Lot 2 or Lot 3), and have post-vaccination data, from which are excluded participants with protocol deviations and for whom immunogenicity results were available for the specified assay and time point.

End point type	Primary
----------------	---------

End point timeframe:

At Day 31

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint had the purpose to only analyse lot-to-lot RSV groups RSV lot 1, RSV lot 2, RSV lot 3).

End point values	RSV lot1 Group	RSV lot2 Group	RSV lot3 Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	201	204	207	
Units: EU/mL				
geometric mean (confidence interval 95%)	102811.0 (95243.6 to 110979.6)	100635.8 (92970.2 to 108933.4)	108709.3 (101913.7 to 115958.0)	

Statistical analyses

Statistical analysis title	RSV lot1 Group to RSV lot2 Group consistency
Statistical analysis description: To demonstrate lot-to-lot consistency of the immune responses of Lot 1 and Lot 2 of the RSV MAT vaccine, as measured by ELISA in terms of IgG GMCs at Day 31.	
Comparison groups	RSV lot1 Group v RSV lot2 Group
Number of subjects included in analysis	405
Analysis specification	Pre-specified
Analysis type	other ^[12]
Method	GMC ratio
Parameter estimate	GMC Ratio
Point estimate	1.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.92
upper limit	1.13

Notes:

[12] - The lot-to-lot consistency is demonstrated only if two-sided 95% confidence intervals (CI) for the 3 pair-wise geometric mean ratios of RSV MAT IgG ELISA concentration falls within 0.67 and 1.5.

Statistical analysis title	RSV lot1 Group to RSV lot3 Group consistency
Statistical analysis description: To demonstrate lot-to-lot consistency of the immune responses of Lot 1 and Lot 3 of the RSV MAT vaccine, as measured by ELISA in terms of IgG GMCs at Day 31.	
Comparison groups	RSV lot1 Group v RSV lot3 Group
Number of subjects included in analysis	408
Analysis specification	Pre-specified
Analysis type	other ^[13]
Method	GMC ratio
Parameter estimate	GMC ratio
Point estimate	0.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.85
upper limit	1.05

Notes:

[13] - The lot-to-lot consistency is demonstrated only if two-sided 95% confidence intervals (CI) for the 3 pair-wise geometric mean ratios of RSV MAT IgG ELISA concentration falls within 0.67 and 1.5.

Statistical analysis title	RSV lot2 Group to RSV lot3 Group consistency
Statistical analysis description: To demonstrate lot-to-lot consistency of the immune responses of Lot 2 and Lot 3 of the RSV MAT vaccine, as measured by ELISA in terms of IgG GMCs at Day 31.	
Comparison groups	RSV lot2 Group v RSV lot3 Group

Number of subjects included in analysis	411
Analysis specification	Pre-specified
Analysis type	other ^[14]
Method	GMC ratio
Parameter estimate	GMC ratio
Point estimate	0.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.83
upper limit	1.03

Notes:

[14] - The lot-to-lot consistency is demonstrated only if two-sided 95% confidence intervals (CI) for the 3 pair-wise geometric mean ratios of RSV MAT IgG ELISA concentration falls within 0.67 and 1.5.

Primary: Flu D-QIV haemagglutinin inhibition (HI) antibody titers against 3 influenza strains for participants in Flu+Placebo Group and RSV+Flu pooled Group at Day 31

End point title	Flu D-QIV haemagglutinin inhibition (HI) antibody titers against 3 influenza strains for participants in Flu+Placebo Group and RSV+Flu pooled Group at Day 31 ^[15]
-----------------	---

End point description:

Flu D-QIV HI antibody titers against 3 influenza strains (A/Tasmania/503/2020 (H3N2) IVR-221; B/Washington/02/2019; B/Phuket/3073/2013) were expressed as geometric mean titers (GMTs), as assessed by HI assay. This objective analyzed the humoral immune response to the Flu D-QIV vaccine when given alone and co-administered with RSV MAT vaccine in terms of antibody titers against 3 influenza strains. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled RSV+Flu Group and Flu+Placebo Group, since minimal differences were expected between participants who received different RSV lots of the vaccine. Analysis was performed on the Per Protocol Set (PPS), only on the participants who received 1 dose of Flu D-QIV vaccine and optionally other study treatment, and have post-vaccination data, from which are excluded participants with protocol deviations and for whom immunogenicity results were available for the specified assay and time point.

End point type	Primary
----------------	---------

End point timeframe:

At Day 31

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint considered only participants who received Flu vaccination and optionally other study interventions, therefore only the Flu groups were considered for statistical analyses.

End point values	RSV+Flu pooled Group	Flu+Placebo Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	398	404		
Units: Titers				
geometric mean (confidence interval 95%)				
A/Tasmania/503/2020 (H3N2)	301.6 (274.0 to 331.9)	421.3 (383.4 to 463.0)		
B/Washington/02/2019	30.7 (27.3 to 34.6)	33.0 (29.3 to 37.2)		
B/Phuket/3073/2013	56.2 (50.7 to 62.3)	69.9 (62.6 to 77.9)		

Statistical analyses

Statistical analysis title	A/Tasmania/503/2020 (H3N2) IVR-221 strain
Statistical analysis description:	
To demonstrate the immunological non-inferiority of the Flu D-QIV vaccine when co-administered with RSV MAT vaccine compared to Flu D-QIV vaccine given alone as measured by the ratio of HI GMTs of Flu D-QIV antibody titers against A/Tasmania/503/2020 (H3N2) IVR-221 strain at 30 days post administration (Day 31).	
Comparison groups	RSV+Flu pooled Group v Flu+Placebo Group
Number of subjects included in analysis	802
Analysis specification	Pre-specified
Analysis type	other ^[16]
Method	GMC ratio
Parameter estimate	GMC ratio
Point estimate	0.72
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.63
upper limit	0.82

Notes:

[16] - The non-inferiority of Flu D-QIV vaccine is demonstrated for the A/Tasmania/503/2020 (H3N2) IVR-221 strain, if the lower limit (LL) of the 95% CI on the GMT ratio (RSV MAT + Flu D-QIV vaccine divided by Flu D-QIV vaccine) is greater than 0.67 at Day 31 post vaccination.

Statistical analysis title	B/Phuket/3073/2013 strain
Statistical analysis description:	
To demonstrate the immunological non-inferiority of the Flu D-QIV vaccine when co-administered with RSV MAT vaccine compared to Flu D-QIV vaccine given alone as measured by the ratio of HI GMTs of Flu D-QIV antibody titers against B/Phuket/3073/2013 strain at 30 days post administration (Day 31).	
Comparison groups	RSV+Flu pooled Group v Flu+Placebo Group
Number of subjects included in analysis	802
Analysis specification	Pre-specified
Analysis type	other ^[17]
Method	GMC ratio
Parameter estimate	GMC ratio
Point estimate	0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.69
upper limit	0.93

Notes:

[17] - The non-inferiority of Flu D-QIV vaccine is demonstrated for B/Phuket/3073/2013 strain, if the lower limit (LL) of the 95% CI on the GMT ratio (RSV MAT + Flu D-QIV vaccine divided by Flu D-QIV vaccine) is greater than 0.67 at Day 31 post vaccination.

Statistical analysis title	B/Washington/02/2019 strain
-----------------------------------	-----------------------------

Statistical analysis description:

To demonstrate the immunological non-inferiority of the Flu D-QIV vaccine when co-administered with RSV MAT vaccine compared to Flu D-QIV vaccine given alone as measured by the ratio of HI GMTs of Flu D-QIV antibody titers against B/Washington/02/2019 strain at 30 days post administration (Day 31).

Comparison groups	RSV+Flu pooled Group v Flu+Placebo Group
Number of subjects included in analysis	802
Analysis specification	Pre-specified
Analysis type	other ^[18]
Method	GMC ratio
Parameter estimate	GMC ratio
Point estimate	0.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.79
upper limit	1.1

Notes:

[18] - The non-inferiority of Flu D-QIV vaccine is demonstrated for B/Washington/02/2019 strain, if the lower limit (LL) of the 95% CI on the GMT ratio (RSV MAT + Flu D-QIV vaccine divided by Flu D-QIV vaccine) is greater than 0.67 at Day 31 post vaccination.

Secondary: RSV A neutralizing antibody titers for participants in RSV pooled Group and RSV+Flu pooled Group at Day 1 and Day 31

End point title	RSV A neutralizing antibody titers for participants in RSV pooled Group and RSV+Flu pooled Group at Day 1 and Day 31 ^[19]
-----------------	--

End point description:

Serological assays for the determination of antibodies against RSV A were performed by neutralization assay. RSV A neutralizing antibody titers were expressed as geometric mean titers (GMTs), in serum dilution inducing 60% inhibition in plaque forming units (ED60). This objective analyzed the humoral immune response of RSV MAT vaccine when given alone and co-administered with Flu D-QIV in terms of RSV A neutralizing antibody. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled groups, since minimal differences were expected between participants who received different RSV lots of the vaccine. Analysis was performed on the Per Protocol Set (PPS), only on the participants who received 1 dose of RSV MAT vaccine and optionally other study treatment, and have post-vaccination data, from which are excluded participants with protocol deviations and for whom immunogenicity results were available for the specified assay and time point.

End point type	Secondary
----------------	-----------

End point timeframe:

At Day 1 and Day 31

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint considered only participants who received RSV vaccination and optionally other study interventions, therefore only the RSV groups were considered for statistical analyses.

End point values	RSV+Flu pooled Group	RSV pooled Group		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	436	657		
Units: Titers				
geometric mean (confidence interval 95%)				
Day 1 (N=657,436)	707.2 (653.4 to 765.5)	721.6 (676.5 to 769.7)		
Day 31 (N=611,398)	7761.6 (7092.8 to 8493.6)	8900.9 (8272.1 to 9577.5)		

Statistical analyses

Statistical analysis title	RSV MAT compared with Flu D-QIV
Statistical analysis description:	
To demonstrate the immunological non-inferiority of the RSV MAT vaccine when co-administered with Flu D-QIV vaccine, compared to RSV MAT vaccine given alone as measured by the ratio of GMTs of RSV A neutralizing antibody titers at 30 days post administration (Day 31).	
Comparison groups	RSV+Flu pooled Group v RSV pooled Group
Number of subjects included in analysis	1093
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[20]
Method	GMC ratio
Parameter estimate	GMC ratio
Point estimate	0.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.78
upper limit	0.97

Notes:

[20] - The non-inferiority of RSV MAT vaccine is demonstrated for RSV A neutralizing antibody titers, if the LL of the 95% CI on the GMT ratio (RSV MAT + Flu D-QIV vaccine divided by RSV MAT vaccine) is greater than 0.67 at Day 31 post vaccination.

Secondary: Seroconversion rate (SCR) to Flu D-QIV HI antibody titers against 3 influenza strains for participants in Flu+Placebo group and RSV+Flu pooled group at Day 31

End point title	Seroconversion rate (SCR) to Flu D-QIV HI antibody titers against 3 influenza strains for participants in Flu+Placebo group and RSV+Flu pooled group at Day 31 ^[21]
-----------------	--

End point description:

The SCR was defined as the percentage of participants with: a Day 1 (pre-vaccination) serum anti-HI titer <1:10 and a Day 31 (post-vaccination) serum anti-HI titer ≥1:40, or a Day 1 (pre-vaccination) serum anti-HI titer ≥ 1:10 and a fold increase (post/pre) ≥ 4 at Day 31. This objective analyzed the seroconversion rate to the Flu D-QIV vaccine when given alone and co-administered with RSV MAT vaccine. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled groups, since minimal differences were expected between participants who received different RSV lots of the vaccine.

Analysis was performed on the PPS, only on the participants who received 1 dose of Flu D-QIV vaccine and optionally other study treatment, and have post-vaccination data, from which are excluded participants with protocol deviations and for whom immunogenicity results were available for the specified assay and time point.

End point type	Secondary
----------------	-----------

End point timeframe:

At Day 31

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint considered only participants who received Flu vaccination and optionally other study interventions, therefore only the Flu groups were considered for statistical analyses.

End point values	RSV+Flu pooled Group	Flu+Placebo Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	398	403		
Units: Percentage of participants				
number (confidence interval 95%)				
A/Tasmania/503/2020 (H3N2)	42.5 (37.6 to 47.5)	45.9 (41 to 50.9)		
B/Washington/02/2019	25.4 (21.2 to 30)	29.5 (25.1 to 34.2)		
B/Phuket/3073/2013	31.4 (26.9 to 36.2)	35.5 (30.8 to 40.4)		

Statistical analyses

Statistical analysis title	A/Tasmania/503/2020 (H3N2) IVR-221 strain
Statistical analysis description:	
To demonstrate the immunological non-inferiority of the Flu D-QIV vaccine when co-administered with RSV MAT vaccine compared to Flu D-QIV vaccine given alone as measured by the difference of proportion of participants achieving seroconversion for HI antibody titers against A/Tasmania/503/2020 (H3N2) IVR-221 strain at 30 days post administration (Day 31).	
Comparison groups	RSV+Flu pooled Group v Flu+Placebo Group
Number of subjects included in analysis	801
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[22]
Method	Miettinen and Nurminen
Parameter estimate	Difference of Proportion
Point estimate	3.44
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.44
upper limit	10.29

Notes:

[22] - The non-inferiority of Flu D-QIV vaccine is demonstrated with respect to the SCR difference for Flu D-QIV antibody titers against A/Tasmania/503/2020 (H3N2) IVR-221 strain, if the upper limit (UL) of the 95% CI on the SCR difference (Flu D-QIV vaccine minus RSV MAT + Flu D-QIV vaccine) is less than or equal to the pre-defined clinical limit of 10% at Day 31 post vaccination.

Statistical analysis title	B/Phuket/3073/2013 strain
Statistical analysis description:	
To demonstrate the immunological non-inferiority of the Flu D-QIV vaccine when co-administered with RSV MAT vaccine compared to Flu D-QIV vaccine given alone as measured by the difference of proportion of participants achieving seroconversion for HI antibody titers against B/Phuket/3073/2013 strain at 30 days post administration (Day 31).	
Comparison groups	RSV+Flu pooled Group v Flu+Placebo Group
Number of subjects included in analysis	801
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[23]
Method	Miettinen and Nurminen
Parameter estimate	Difference of Proportion
Point estimate	4.08

Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.46
upper limit	10.58

Notes:

[23] - The non-inferiority of Flu D-QIV vaccine is demonstrated with respect to the SCR difference for Flu D-QIV antibody titers against B/Phuket/3073/2013 strain, if the upper limit (UL) of the 95% CI on the SCR difference (Flu D-QIV vaccine minus RSV MAT + Flu D-QIV vaccine) is less than or equal to the pre-defined clinical limit of 10% at Day 31 post vaccination.

Statistical analysis title	B/Washington/02/2019 strain
-----------------------------------	-----------------------------

Statistical analysis description:

To demonstrate the immunological non-inferiority of the Flu D-QIV vaccine when co-administered with RSV MAT vaccine compared to Flu D-QIV vaccine given alone as measured by the difference of proportion of participants achieving seroconversion for HI antibody titers against B/Washington/02/2019 strain at 30 days post administration (Day 31).

Comparison groups	RSV+Flu pooled Group v Flu+Placebo Group
Number of subjects included in analysis	801
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[24]
Method	Miettinen and Nurminen
Parameter estimate	Difference of Proportion
Point estimate	4.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.04
upper limit	10.32

Notes:

[24] - The non-inferiority of Flu D-QIV vaccine is demonstrated with respect to the SCR difference for Flu D-QIV antibody titers against B/Washington/02/2019 strain, if the upper limit (UL) of the 95% CI on the SCR difference (Flu D-QIV vaccine minus RSV MAT + Flu D-QIV vaccine) is less than or equal to the pre-defined clinical limit of 10% at Day 31 post vaccination.

Secondary: RSV B neutralizing antibody titers for participants in RSV pooled Group and RSV+Flu pooled Group at Day 1 and Day 31

End point title	RSV B neutralizing antibody titers for participants in RSV pooled Group and RSV+Flu pooled Group at Day 1 and Day 31 ^[25]
-----------------	--

End point description:

Serological assays for the determination of antibodies against RSV B were performed by neutralization assay. RSV B neutralizing antibody titers were expressed as GMTs, in ED60. This objective analyzed the humoral immune response of RSV MAT vaccine when given alone and co-administered with Flu D-QIV in terms of RSV B neutralizing antibody. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled RSV and RSV+Flu groups, since minimal differences were expected between participants who received different RSV lots of the vaccine.

Analysis was performed on the Per Protocol Set (PPS), only on the participants who received 1 dose of RSV MAT vaccine (from one of the 3 lots used) and optionally other study treatment, and have post-vaccination data, from which are excluded participants with protocol deviations and for whom immunogenicity results were available for the specified assay and time point.

End point type	Secondary
----------------	-----------

End point timeframe:

At Day 1 and Day 31

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint considered only participants who received RSV vaccination and optionally

other study interventions, therefore only the RSV groups were considered for statistical analyses.

End point values	RSV+Flu pooled Group	RSV pooled Group		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	436	656		
Units: Titers				
geometric mean (confidence interval 95%)				
Day 1 (N=656,436)	940.1 (871 to 1014.6)	967.4 (909.5 to 1028.9)		
Day 31 (N=610,398)	9162.3 (8483.3 to 9895.8)	11030.5 (10344.5 to 11762)		

Statistical analyses

No statistical analyses for this end point

Secondary: RSV MAT IgG concentrations for participants in RSV pooled Group and RSV+Flu pooled Group at Day 1 and Day 31

End point title	RSV MAT IgG concentrations for participants in RSV pooled Group and RSV+Flu pooled Group at Day 1 and Day 31 ^[26]
-----------------	--

End point description:

Serological assays for the determination of IgG antibodies against RSV MAT were performed by ELISA. RSV MAT IgG concentrations were expressed as GMCs, in EU/mL. This objective analyzed the humoral immune response of RSV MAT vaccine when given alone and co-administered with Flu D-QIV in terms of RSV MAT IgG concentrations. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled RSV and RSV+Flu groups, since minimal differences were expected between participants who received different RSV lots of the vaccine.

Analysis was performed on the Per Protocol Set (PPS), only on the participants who received 1 dose of RSV MAT vaccine (from one of the 3 lots used) and optionally other study treatment, and have post-vaccination data, from which are excluded participants with protocol deviations and for whom immunogenicity results were available for the specified assay and time point.

End point type	Secondary
----------------	-----------

End point timeframe:

At Day 1 and Day 31

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint considered only participants who received RSV vaccination and optionally other study interventions, therefore only the RSV groups were considered for statistical analyses.

End point values	RSV+Flu pooled Group	RSV pooled Group		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	436	657		
Units: EU/mL				
geometric mean (confidence interval 95%)				
Day 1 (N=657,436)	5772 (5455.8 to 6106.4)	5522.7 (5285.7 to 5770.4)		

Day 31 (N=612,398)	83937 (79640.9 to 88464.9)	104025.1 (99714.5 to 108522.2)		
--------------------	----------------------------------	--------------------------------------	--	--

Statistical analyses

No statistical analyses for this end point

Secondary: Flu D-QIV HI antibody titers against 3 influenza strains for participants in Flu+Placebo Group and RSV+Flu pooled Group at Day 1 and Day 31

End point title	Flu D-QIV HI antibody titers against 3 influenza strains for participants in Flu+Placebo Group and RSV+Flu pooled Group at Day 1 and Day 31 ^[27]
-----------------	---

End point description:

Flu D-QIV HI antibody titers against 3 influenza strains (A/Tasmania/503/2020 (H3N2) IVR-221; B/Washington/02/2019; B/Phuket/3073/2013) were expressed as geometric mean titers (GMTs), as assessed by HI assay. This objective analyzed the humoral immune response to the Flu D-QIV vaccine when given alone and co-administered with RSV MAT vaccine in terms of antibody titers against 3 influenza strains. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled RSV+Flu Group and Flu+Placebo Group, since minimal differences were expected between participants who received different RSV lots of the vaccine.

Analysis was performed on the Per Protocol Set (PPS), only on the participants who received 1 dose of Flu D-QIV vaccine and optionally other study treatment, and have post-vaccination data, from which are excluded participants with protocol deviations and for whom immunogenicity results were available for the specified assay and time point.

End point type	Secondary
----------------	-----------

End point timeframe:

At Day 1 and Day 31

Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint considered only participants who received Flu vaccination and optionally other study interventions, therefore only the Flu groups were considered for statistical analyses.

End point values	RSV+Flu pooled Group	Flu+Placebo Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	436	437		
Units: Titers				
geometric mean (confidence interval 95%)				
A/Tasmania/503/2020 (H3N2) , Day 1 (N=436,437)	92.2 (81.2 to 104.8)	110.3 (97.2 to 125.1)		
A/Tasmania/503/2020 (H3N2) , Day 31 (N=398,404)	301.6 (274 to 331.9)	421.3 (383.4 to 463)		
B/Washington/02/2019 , Day 1 (N=436,437)	11.7 (10.6 to 13)	10.3 (9.4 to 11.3)		
B/Washington/02/2019 , Day 31 (N=398,404)	30.7 (27.3 to 34.6)	33 (29.3 to 37.2)		
B/Phuket/3073/2013 , Day 1 (N=436,437)	21.2 (19 to 23.7)	21.9 (19.6 to 24.5)		
B/Phuket/3073/2013 , Day 31 (N=398,404)	56.2 (50.7 to 62.3)	69.9 (62.6 to 77.9)		

Statistical analyses

No statistical analyses for this end point

Secondary: Seroprotection rate (SPR) to Flu D-QIV HI antibody titers for participants in Flu+Placebo Group and RSV+Flu pooled Group at Day 1 and Day 31

End point title	Seroprotection rate (SPR) to Flu D-QIV HI antibody titers for participants in Flu+Placebo Group and RSV+Flu pooled Group at Day 1 and Day 31 ^[28]
-----------------	--

End point description:

SPR was measured by the percentage of participants achieving an HI antibody titer $\geq 1:40$. This objective analyzed the seroprotection rate to the Flu D-QIV vaccine when given alone and co-administered with RSV MAT vaccine. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled RSV+Flu Group and Flu+Placebo Group, since minimal differences were expected between participants who received different RSV lots of the vaccine.

Analysis was performed on the Per Protocol Set (PPS), only on the participants who received 1 dose of Flu D-QIV vaccine and optionally other study treatment, and have post-vaccination data, from which are excluded participants with protocol deviations and for whom immunogenicity results were available for the specified assay and time point.

End point type	Secondary
----------------	-----------

End point timeframe:

At Day 1 and Day 31

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint considered only participants who received Flu vaccination and optionally other study interventions, therefore only the Flu groups were considered for statistical analyses.

End point values	RSV+Flu pooled Group	Flu+Placebo Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	436	437		
Units: Percentage of participants				
number (confidence interval 95%)				
A/Tasmania/503/2020 (H3N2) , Day 1 (N=436,437)	78.7 (74.5 to 82.4)	82.8 (79 to 86.3)		
A/Tasmania/503/2020 (H3N2) , Day 31 (N=398,404)	98 (96.1 to 99.1)	98.5 (96.8 to 99.5)		
B/Washington/02/2019 , Day 1 (N=436,437)	19.7 (16.1 to 23.8)	16.9 (13.5 to 20.8)		
B/Washington/02/2019 , Day 31 (N=398,404)	48 (43 to 53)	48.8 (43.8 to 53.8)		
B/Phuket/3073/2013 , Day 1 (N=436,437)	36.7 (32.2 to 41.4)	39.8 (35.2 to 44.6)		
B/Phuket/3073/2013 , Day 31 (N=398,404)	74.4 (69.8 to 78.6)	77.2 (72.8 to 81.2)		

Statistical analyses

No statistical analyses for this end point

Secondary: RSV A neutralizing antibody titers for participants in RSV lot1, RSV lot2 and RSV lot3 groups at Day 1 and Day 31

End point title	RSV A neutralizing antibody titers for participants in RSV lot1, RSV lot2 and RSV lot3 groups at Day 1 and Day 31 ^[29]
-----------------	---

End point description:

Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay. RSV A neutralizing antibody titers were expressed as GMTs, in ED60. As pre-specified in protocol, data reported in this outcome measure was presented only for individual RSV lot groups (RSV lot1, RSV lot2, RSV lot3), as the purpose was to analyze the humoral immune response of RSV A neutralizing antibody titers, in order to demonstrate the lot-to-lot consistency of the vaccine lots.

Analysis was performed on the Per Protocol Set (PPS), only on the participants who received only 1 dose of RSV MAT vaccine (from RSV MAT vaccine Lot 1, Lot 2 or Lot 3), and have post-vaccination data, from which are excluded participants with protocol deviations and for whom immunogenicity results were available for the specified assay and time point.

End point type	Secondary
----------------	-----------

End point timeframe:

At Day 1 and Day 31

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint had the purpose to only analyse lot-to-lot RSV groups RSV lot 1, RSV lot 2, RSV lot 3).

End point values	RSV lot1 Group	RSV lot2 Group	RSV lot3 Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	217	223	217	
Units: TITers				
geometric mean (confidence interval 95%)				
Day 1 (N=217, 223, 217)	727.5 (652 to 811.6)	758.4 (676.7 to 849.9)	680.2 (607.4 to 761.7)	
Day 31 (N=201, 204, 206)	8545.5 (7464.4 to 9783.2)	8760.3 (7716.2 to 9945.8)	9409.2 (8343.5 to 10611)	

Statistical analyses

No statistical analyses for this end point

Secondary: RSV B neutralizing antibody titers for participants in RSV lot1, RSV lot2 and RSV lot3 groups at Day 1 and Day 31

End point title	RSV B neutralizing antibody titers for participants in RSV lot1, RSV lot2 and RSV lot3 groups at Day 1 and Day 31 ^[30]
-----------------	---

End point description:

Serological assays for the determination of antibodies against RSV B were performed by neutralization assay. RSV B neutralizing antibody titers were expressed as GMTs, in ED60. As pre-specified in protocol, data reported in this outcome measure was presented only for individual RSV lot groups (RSV lot1, RSV lot2, RSV lot3), as the purpose was to analyze the humoral immune response of RSV B neutralizing antibody titers, in order to demonstrate the lot-to-lot consistency of the vaccine lots.

Analysis was performed on the Per Protocol Set (PPS), only on the participants who received only 1 dose of RSV MAT vaccine (from RSV MAT vaccine Lot 1, Lot 2 or Lot 3), and have post-vaccination data, from

which are excluded participants with protocol deviations and for whom immunogenicity results were available for the specified assay and time point.

End point type	Secondary
----------------	-----------

End point timeframe:

At Day 1 and Day 31

Notes:

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint had the purpose to only analyse lot-to-lot RSV groups RSV lot 1, RSV lot 2, RSV lot 3).

End point values	RSV lot1 Group	RSV lot2 Group	RSV lot3 Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	216	223	217	
Units: Titers				
geometric mean (confidence interval 95%)				
Day 1 (N=216, 223, 217)	895 (810.6 to 988.2)	1030.3 (929.3 to 1142.3)	979.7 (870.6 to 1102.4)	
Day 31 (N=201, 204, 205)	10457 (9258.5 to 11810.6)	11107.2 (9984.4 to 12356.4)	11543.3 (10377.6 to 12840.1)	

Statistical analyses

No statistical analyses for this end point

Secondary: RSV MAT IgG concentrations for participants in RSV lot1, RSV lot2 and RSV lot3 groups at Day 1 and Day 31

End point title	RSV MAT IgG concentrations for participants in RSV lot1, RSV lot2 and RSV lot3 groups at Day 1 and Day 31 ^[31]
-----------------	---

End point description:

Serological assays for the determination of IgG antibodies against RSV MAT were performed by ELISA. RSV MAT IgG concentrations were expressed as GMCs, in EU/mL. As pre-specified in protocol, data reported in this outcome measure was presented only for individual RSV lot groups (RSV lot1, RSV lot2, RSV lot3), as the purpose was to analyze the RSV MAT IgG concentration, in order to demonstrate the lot-to-lot consistency of the vaccine lots.

Analysis was performed on the Per Protocol Set (PPS), only on the participants who received only 1 dose of RSV MAT vaccine (from RSV MAT vaccine Lot 1, Lot 2 or Lot 3), and have post-vaccination data, from which are excluded participants with protocol deviations and for whom immunogenicity results were available for the specified assay and time point.

End point type	Secondary
----------------	-----------

End point timeframe:

At Day 1 and Day 31

Notes:

[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint had the purpose to only analyse lot-to-lot RSV groups RSV lot 1, RSV lot 2, RSV lot 3).

End point values	RSV lot1 Group	RSV lot2 Group	RSV lot3 Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	217	223	217	
Units: EU/mL				
geometric mean (confidence interval 95%)				
Day 1 (N=217, 223, 217)	5691.9 (5276.8 to 6139.7)	5613 (5197.8 to 6061.3)	5270.1 (4883.6 to 5687.1)	
Day 31 (N=201, 204, 207)	102811 (95243.6 to 110979.6)	100635.8 (92970.2 to 108933.4)	108709.3 (101913.7 to 115958)	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Serious Adverse Events (SAEs) were collected through the entire period of the study (from Day 1 up to study end [Day 181]). Solicited AEs were collected from Day 1 to Day 7 included and unsolicited AEs were collected from Day 1 to Day 30 included.

Adverse event reporting additional description:

As pre-specified in protocol, adverse events were presented for individual RSV lot groups, RSV+Flu pooled Group and Flu+Placebo group. Participants that received the Flu vaccine only as standard of care (group RSV pooled) were not included for safety analyses after receiving the Flu vaccine, as this was not a study objective.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	25.0

Reporting groups

Reporting group title	RSV lot1 Group
-----------------------	----------------

Reporting group description:

Participants randomized to the RSV lot1 Group received one dose of RSV MAT Lot 1 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.

Reporting group title	RSV lot2 Group
-----------------------	----------------

Reporting group description:

Participants randomized to the RSV lot2 Group received one dose of RSV MAT Lot 2 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.

Reporting group title	RSV lot3 Group
-----------------------	----------------

Reporting group description:

Participants randomized to the RSV lot3 Group received one dose of RSV MAT Lot 3 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.

Reporting group title	RSV+Flu pooled Group
-----------------------	----------------------

Reporting group description:

Participants randomized in this group received one dose of RSVPreF3 vaccine (RSV MAT vaccine) from one of the three lots used (Lot 1, Lot 2 or Lot 3 of same formulation of RSVPreF3 vaccine) and one dose of the Flu D-QIV vaccine on Day 1, and were followed up until the end of the study (Day 181). The participants in this group were considered for the immunogenicity and safety analyses of the RSV MAT and Flu D-QIV vaccines.

Reporting group title	Flu+Placebo Group
-----------------------	-------------------

Reporting group description:

Participants randomized in this group received one dose of Flu D-QIV vaccine co-administered with one dose of placebo at Day 1, and were followed up until the end of the study (Day 181). This group was considered comparator for immunogenicity and safety analyses for RSV+ Flu Pooled group.

Serious adverse events	RSV lot1 Group	RSV lot2 Group	RSV lot3 Group
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 220 (0.91%)	1 / 223 (0.45%)	2 / 218 (0.92%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Injury, poisoning and procedural complications			
Fibula fracture			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	1 / 218 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Overdose			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ligament rupture			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple fractures			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Optic neuropathy			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Cervical dysplasia			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	1 / 218 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Suicidal ideation			

subjects affected / exposed	1 / 220 (0.45%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Joint ankylosis			
subjects affected / exposed	1 / 220 (0.45%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	0 / 220 (0.00%)	1 / 223 (0.45%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Greater trochanteric pain syndrome			
subjects affected / exposed	0 / 220 (0.00%)	1 / 223 (0.45%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	RSV+Flu pooled Group	Flu+Placebo Group	
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 438 (0.91%)	4 / 440 (0.91%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Injury, poisoning and procedural complications			
Fibula fracture			
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Overdose			
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament rupture			
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple fractures			
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Optic neuropathy			
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Cervical dysplasia			
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			

Cholelithiasis			
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Suicidal ideation			
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicide attempt			
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Joint ankylosis			
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Greater trochanteric pain syndrome			
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion			
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Appendicitis			

subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19 pneumonia			
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	RSV lot1 Group	RSV lot2 Group	RSV lot3 Group
Total subjects affected by non-serious adverse events			
subjects affected / exposed	182 / 220 (82.73%)	193 / 223 (86.55%)	194 / 218 (88.99%)
Vascular disorders			
Hot flush			
subjects affected / exposed	0 / 220 (0.00%)	1 / 223 (0.45%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Hypertension			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Administration site erythema			
subjects affected / exposed	10 / 220 (4.55%)	9 / 223 (4.04%)	10 / 218 (4.59%)
occurrences (all)	10	9	10
Administration site swelling			
subjects affected / exposed	9 / 220 (4.09%)	11 / 223 (4.93%)	10 / 218 (4.59%)
occurrences (all)	9	11	10
Fatigue			
subjects affected / exposed	110 / 220 (50.00%)	113 / 223 (50.67%)	121 / 218 (55.50%)
occurrences (all)	112	113	123
Administration site pain			
subjects affected / exposed	108 / 220 (49.09%)	131 / 223 (58.74%)	115 / 218 (52.75%)
occurrences (all)	108	131	115
Pyrexia			

subjects affected / exposed	6 / 220 (2.73%)	3 / 223 (1.35%)	8 / 218 (3.67%)
occurrences (all)	6	3	8
Pain			
subjects affected / exposed	1 / 220 (0.45%)	2 / 223 (0.90%)	1 / 218 (0.46%)
occurrences (all)	1	2	1
Chills			
subjects affected / exposed	0 / 220 (0.00%)	2 / 223 (0.90%)	0 / 218 (0.00%)
occurrences (all)	0	2	0
Chest pain			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Injection site pruritus			
subjects affected / exposed	0 / 220 (0.00%)	1 / 223 (0.45%)	1 / 218 (0.46%)
occurrences (all)	0	1	1
Injection site haematoma			
subjects affected / exposed	0 / 220 (0.00%)	1 / 223 (0.45%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Injection site swelling			
subjects affected / exposed	1 / 220 (0.45%)	1 / 223 (0.45%)	0 / 218 (0.00%)
occurrences (all)	1	1	0
Asthenia			
subjects affected / exposed	0 / 220 (0.00%)	1 / 223 (0.45%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Influenza like illness			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Administration site warmth			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Injection site discomfort			
subjects affected / exposed	1 / 220 (0.45%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	1	0	0
Injection site extravasation			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Vaccination site haematoma			

subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Vaccination site rash			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Chest discomfort			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Discomfort			
subjects affected / exposed	1 / 220 (0.45%)	0 / 223 (0.00%)	2 / 218 (0.92%)
occurrences (all)	1	0	4
Injection site lymphadenopathy			
subjects affected / exposed	0 / 220 (0.00%)	3 / 223 (1.35%)	2 / 218 (0.92%)
occurrences (all)	0	3	2
Injection site pain			
subjects affected / exposed	4 / 220 (1.82%)	1 / 223 (0.45%)	0 / 218 (0.00%)
occurrences (all)	4	1	0
Swelling			
subjects affected / exposed	5 / 220 (2.27%)	1 / 223 (0.45%)	1 / 218 (0.46%)
occurrences (all)	5	1	1
Axillary pain			
subjects affected / exposed	4 / 220 (1.82%)	5 / 223 (2.24%)	4 / 218 (1.83%)
occurrences (all)	4	5	4
Malaise			
subjects affected / exposed	0 / 220 (0.00%)	2 / 223 (0.90%)	0 / 218 (0.00%)
occurrences (all)	0	2	0
Feeling hot			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Injection site erythema			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Temperature regulation disorder			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Vaccination site pain			

subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	0 / 223 (0.00%) 0	0 / 218 (0.00%) 0
Immune system disorders Food allergy subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	0 / 223 (0.00%) 0	0 / 218 (0.00%) 0
Immunisation reaction subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	0 / 223 (0.00%) 0	0 / 218 (0.00%) 0
Social circumstances High risk sexual behaviour subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	1 / 223 (0.45%) 1	0 / 218 (0.00%) 0
Reproductive system and breast disorders Dysmenorrhoea subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	1 / 223 (0.45%) 1	0 / 218 (0.00%) 0
Menstrual disorder subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	0 / 223 (0.00%) 0	1 / 218 (0.46%) 1
Heavy menstrual bleeding subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	0 / 223 (0.00%) 0	0 / 218 (0.00%) 0
Intermenstrual bleeding subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	0 / 223 (0.00%) 0	0 / 218 (0.00%) 0
Menstruation irregular subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	0 / 223 (0.00%) 0	0 / 218 (0.00%) 0
Menopausal symptoms subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	0 / 223 (0.00%) 0	0 / 218 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain subjects affected / exposed occurrences (all)	3 / 220 (1.36%) 3	3 / 223 (1.35%) 3	5 / 218 (2.29%) 5

Rhinorrhoea			
subjects affected / exposed	1 / 220 (0.45%)	2 / 223 (0.90%)	4 / 218 (1.83%)
occurrences (all)	1	2	4
Nasal congestion			
subjects affected / exposed	0 / 220 (0.00%)	3 / 223 (1.35%)	2 / 218 (0.92%)
occurrences (all)	0	4	2
Productive cough			
subjects affected / exposed	0 / 220 (0.00%)	1 / 223 (0.45%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Dyspnoea			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Catarrh			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Sinus congestion			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Cough			
subjects affected / exposed	2 / 220 (0.91%)	2 / 223 (0.90%)	1 / 218 (0.46%)
occurrences (all)	2	2	1
Sneezing			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Paranasal sinus discomfort			
subjects affected / exposed	0 / 220 (0.00%)	1 / 223 (0.45%)	0 / 218 (0.00%)
occurrences (all)	0	2	0
Rhinitis allergic			
subjects affected / exposed	0 / 220 (0.00%)	1 / 223 (0.45%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Asthma			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Throat irritation			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0

Pulmonary calcification subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	0 / 223 (0.00%) 0	0 / 218 (0.00%) 0
Aphonia subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	1 / 223 (0.45%) 1	0 / 218 (0.00%) 0
Psychiatric disorders			
Insomnia subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	1 / 223 (0.45%) 1	0 / 218 (0.00%) 0
Bipolar disorder subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	0 / 223 (0.00%) 0	0 / 218 (0.00%) 0
Irritability subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	0 / 223 (0.00%) 0	0 / 218 (0.00%) 0
Investigations			
Smear cervix abnormal subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	0 / 223 (0.00%) 0	0 / 218 (0.00%) 0
Body temperature increased subjects affected / exposed occurrences (all)	1 / 220 (0.45%) 1	0 / 223 (0.00%) 0	0 / 218 (0.00%) 0
Blood pressure decreased subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	0 / 223 (0.00%) 0	0 / 218 (0.00%) 0
Injury, poisoning and procedural complications			
Fascial rupture subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	0 / 223 (0.00%) 0	0 / 218 (0.00%) 0
Limb injury subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	2 / 223 (0.90%) 2	0 / 218 (0.00%) 0
Fall subjects affected / exposed occurrences (all)	1 / 220 (0.45%) 1	0 / 223 (0.00%) 0	0 / 218 (0.00%) 0

Lip injury			
subjects affected / exposed	0 / 220 (0.00%)	1 / 223 (0.45%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Concussion			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Patella fracture			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Thermal burn			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Animal bite			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Arthropod bite			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Muscle strain			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Congenital, familial and genetic disorders			
Supernumerary teeth			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Headache			
subjects affected / exposed	110 / 220 (50.00%)	108 / 223 (48.43%)	108 / 218 (49.54%)
occurrences (all)	122	115	111
Migraine			
subjects affected / exposed	1 / 220 (0.45%)	1 / 223 (0.45%)	1 / 218 (0.46%)
occurrences (all)	1	1	1
Dizziness			
subjects affected / exposed	0 / 220 (0.00%)	2 / 223 (0.90%)	1 / 218 (0.46%)
occurrences (all)	0	2	1
Hypoaesthesia			

subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Paraesthesia			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Idiopathic intracranial hypertension			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Syncope			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Dizziness exertional			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Lymphadenopathy			
subjects affected / exposed	6 / 220 (2.73%)	7 / 223 (3.14%)	5 / 218 (2.29%)
occurrences (all)	6	8	5
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 220 (0.45%)	1 / 223 (0.45%)	0 / 218 (0.00%)
occurrences (all)	1	1	0
Vertigo positional			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Excessive cerumen production			
subjects affected / exposed	1 / 220 (0.45%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	1	0	0
Ear pain			
subjects affected / exposed	0 / 220 (0.00%)	1 / 223 (0.45%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Eustachian tube disorder			
subjects affected / exposed	0 / 220 (0.00%)	1 / 223 (0.45%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
External ear inflammation			

subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	0 / 223 (0.00%) 0	1 / 218 (0.46%) 1
Eye disorders			
Eye symptom			
subjects affected / exposed	0 / 220 (0.00%)	1 / 223 (0.45%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Blepharitis			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Eczema eyelids			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	34 / 220 (15.45%)	31 / 223 (13.90%)	32 / 218 (14.68%)
occurrences (all)	35	32	33
Diarrhoea			
subjects affected / exposed	29 / 220 (13.18%)	25 / 223 (11.21%)	28 / 218 (12.84%)
occurrences (all)	29	27	28
Abdominal pain			
subjects affected / exposed	25 / 220 (11.36%)	33 / 223 (14.80%)	25 / 218 (11.47%)
occurrences (all)	25	33	25
Vomiting			
subjects affected / exposed	7 / 220 (3.18%)	5 / 223 (2.24%)	3 / 218 (1.38%)
occurrences (all)	7	5	3
Flatulence			
subjects affected / exposed	0 / 220 (0.00%)	2 / 223 (0.90%)	0 / 218 (0.00%)
occurrences (all)	0	2	0
Abdominal pain upper			
subjects affected / exposed	0 / 220 (0.00%)	1 / 223 (0.45%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Gastritis			

subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Constipation			
subjects affected / exposed	0 / 220 (0.00%)	1 / 223 (0.45%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Dyspepsia			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Odynophagia			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Diarrhoea haemorrhagic			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Frequent bowel movements			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Paraesthesia oral			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Volvulus			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids thrombosed			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Urticaria			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Rash			
subjects affected / exposed	2 / 220 (0.91%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	2	0	0

Pruritus			
subjects affected / exposed	0 / 220 (0.00%)	2 / 223 (0.90%)	0 / 218 (0.00%)
occurrences (all)	0	2	0
Erythema			
subjects affected / exposed	0 / 220 (0.00%)	1 / 223 (0.45%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Dermatitis atopic			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Dermatitis			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Rash macular			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Bladder pain			
subjects affected / exposed	1 / 220 (0.45%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	1	0	0
Tubulointerstitial nephritis			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Dysuria			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	2 / 220 (0.91%)	4 / 223 (1.79%)	1 / 218 (0.46%)
occurrences (all)	2	4	1
Arthralgia			
subjects affected / exposed	3 / 220 (1.36%)	0 / 223 (0.00%)	1 / 218 (0.46%)
occurrences (all)	3	0	1
Pain in extremity			

subjects affected / exposed	1 / 220 (0.45%)	0 / 223 (0.00%)	1 / 218 (0.46%)
occurrences (all)	1	0	1
Neck pain			
subjects affected / exposed	1 / 220 (0.45%)	0 / 223 (0.00%)	1 / 218 (0.46%)
occurrences (all)	1	0	1
Synovial cyst			
subjects affected / exposed	0 / 220 (0.00%)	1 / 223 (0.45%)	1 / 218 (0.46%)
occurrences (all)	0	1	1
Back pain			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Muscle contracture			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Torticollis			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Groin pain			
subjects affected / exposed	0 / 220 (0.00%)	1 / 223 (0.45%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Axillary mass			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Bone pain			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Arthritis			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			

subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	0 / 223 (0.00%) 0	0 / 218 (0.00%) 0
Pain in jaw			
subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	0 / 223 (0.00%) 0	0 / 218 (0.00%) 0
Tendonitis			
subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	0 / 223 (0.00%) 0	0 / 218 (0.00%) 0
Infections and infestations			
Pharyngitis			
subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	1 / 223 (0.45%) 1	0 / 218 (0.00%) 0
Nasopharyngitis			
subjects affected / exposed occurrences (all)	4 / 220 (1.82%) 4	4 / 223 (1.79%) 4	2 / 218 (0.92%) 2
Upper respiratory tract infection			
subjects affected / exposed occurrences (all)	4 / 220 (1.82%) 4	0 / 223 (0.00%) 0	3 / 218 (1.38%) 3
COVID-19			
subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	2 / 223 (0.90%) 2	4 / 218 (1.83%) 4
Urinary tract infection			
subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	1 / 223 (0.45%) 1	2 / 218 (0.92%) 2
Sinusitis			
subjects affected / exposed occurrences (all)	1 / 220 (0.45%) 1	1 / 223 (0.45%) 1	2 / 218 (0.92%) 2
Influenza			
subjects affected / exposed occurrences (all)	3 / 220 (1.36%) 3	0 / 223 (0.00%) 0	1 / 218 (0.46%) 1
Bronchitis			
subjects affected / exposed occurrences (all)	0 / 220 (0.00%) 0	0 / 223 (0.00%) 0	3 / 218 (1.38%) 3
Pharyngotonsillitis			
subjects affected / exposed occurrences (all)	1 / 220 (0.45%) 1	2 / 223 (0.90%) 2	0 / 218 (0.00%) 0

Gastroenteritis viral			
subjects affected / exposed	1 / 220 (0.45%)	0 / 223 (0.00%)	1 / 218 (0.46%)
occurrences (all)	1	0	1
Respiratory tract infection			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Tonsillitis			
subjects affected / exposed	0 / 220 (0.00%)	1 / 223 (0.45%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Nasal herpes			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Cystitis			
subjects affected / exposed	1 / 220 (0.45%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	1	0	0
Eczema impetiginous			
subjects affected / exposed	1 / 220 (0.45%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	1	0	0
Laryngitis			
subjects affected / exposed	1 / 220 (0.45%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	1	0	0
Upper respiratory tract infection bacterial			
subjects affected / exposed	1 / 220 (0.45%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	1	0	0
Vulvovaginitis			
subjects affected / exposed	1 / 220 (0.45%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	1	0	0
Ear infection			
subjects affected / exposed	0 / 220 (0.00%)	1 / 223 (0.45%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Oral herpes			
subjects affected / exposed	0 / 220 (0.00%)	1 / 223 (0.45%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Viral infection			

subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Pharyngitis streptococcal			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Bacterial vulvovaginitis			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Fungal infection			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Gingivitis			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Otitis media acute			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection bacterial			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Suspected COVID-19			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Bacterial vaginosis			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Otitis externa			

subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	10
Pneumonia			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection viral			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Streptococcal infection			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 220 (0.00%)	0 / 223 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	RSV+Flu pooled Group	Flu+Placebo Group	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	409 / 438 (93.38%)	396 / 440 (90.00%)	
Vascular disorders			
Hot flush			
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)	
occurrences (all)	1	0	
Hypertension			
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			
Administration site erythema			
subjects affected / exposed	18 / 438 (4.11%)	7 / 440 (1.59%)	
occurrences (all)	19	7	
Administration site swelling			
subjects affected / exposed	32 / 438 (7.31%)	14 / 440 (3.18%)	
occurrences (all)	35	14	
Fatigue			
subjects affected / exposed	263 / 438 (60.05%)	230 / 440 (52.27%)	
occurrences (all)	268	233	

Administration site pain		
subjects affected / exposed	360 / 438 (82.19%)	327 / 440 (74.32%)
occurrences (all)	440	346
Pyrexia		
subjects affected / exposed	14 / 438 (3.20%)	3 / 440 (0.68%)
occurrences (all)	14	3
Pain		
subjects affected / exposed	2 / 438 (0.46%)	0 / 440 (0.00%)
occurrences (all)	2	0
Chills		
subjects affected / exposed	6 / 438 (1.37%)	1 / 440 (0.23%)
occurrences (all)	6	1
Chest pain		
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)
occurrences (all)	0	1
Injection site pruritus		
subjects affected / exposed	2 / 438 (0.46%)	0 / 440 (0.00%)
occurrences (all)	2	0
Injection site haematoma		
subjects affected / exposed	1 / 438 (0.23%)	2 / 440 (0.45%)
occurrences (all)	1	2
Injection site swelling		
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)
occurrences (all)	0	0
Asthenia		
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)
occurrences (all)	0	1
Influenza like illness		
subjects affected / exposed	1 / 438 (0.23%)	2 / 440 (0.45%)
occurrences (all)	1	2
Administration site warmth		
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)
occurrences (all)	0	0
Injection site discomfort		
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)
occurrences (all)	0	0

Injection site extravasation subjects affected / exposed occurrences (all)	1 / 438 (0.23%) 1	0 / 440 (0.00%) 0
Vaccination site haematoma subjects affected / exposed occurrences (all)	1 / 438 (0.23%) 1	0 / 440 (0.00%) 0
Vaccination site rash subjects affected / exposed occurrences (all)	1 / 438 (0.23%) 1	0 / 440 (0.00%) 0
Chest discomfort subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1
Discomfort subjects affected / exposed occurrences (all)	4 / 438 (0.91%) 5	3 / 440 (0.68%) 3
Injection site lymphadenopathy subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	2 / 440 (0.45%) 3
Injection site pain subjects affected / exposed occurrences (all)	1 / 438 (0.23%) 1	5 / 440 (1.14%) 5
Swelling subjects affected / exposed occurrences (all)	3 / 438 (0.68%) 3	1 / 440 (0.23%) 1
Axillary pain subjects affected / exposed occurrences (all)	6 / 438 (1.37%) 6	2 / 440 (0.45%) 3
Malaise subjects affected / exposed occurrences (all)	3 / 438 (0.68%) 4	1 / 440 (0.23%) 1
Feeling hot subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1
Injection site erythema subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1

Temperature regulation disorder subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1	
Vaccination site pain subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1	
Immune system disorders			
Food allergy subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1	
Immunisation reaction subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1	
Social circumstances			
High risk sexual behaviour subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	0 / 440 (0.00%) 0	
Reproductive system and breast disorders			
Dysmenorrhoea subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	2 / 440 (0.45%) 2	
Menstrual disorder subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	0 / 440 (0.00%) 0	
Heavy menstrual bleeding subjects affected / exposed occurrences (all)	1 / 438 (0.23%) 1	0 / 440 (0.00%) 0	
Intermenstrual bleeding subjects affected / exposed occurrences (all)	1 / 438 (0.23%) 1	0 / 440 (0.00%) 0	
Menstruation irregular subjects affected / exposed occurrences (all)	1 / 438 (0.23%) 1	0 / 440 (0.00%) 0	
Menopausal symptoms subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 4	

Respiratory, thoracic and mediastinal disorders			
Oropharyngeal pain			
subjects affected / exposed	6 / 438 (1.37%)	6 / 440 (1.36%)	
occurrences (all)	6	6	
Rhinorrhoea			
subjects affected / exposed	3 / 438 (0.68%)	5 / 440 (1.14%)	
occurrences (all)	3	5	
Nasal congestion			
subjects affected / exposed	6 / 438 (1.37%)	4 / 440 (0.91%)	
occurrences (all)	6	4	
Productive cough			
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)	
occurrences (all)	0	1	
Dyspnoea			
subjects affected / exposed	1 / 438 (0.23%)	2 / 440 (0.45%)	
occurrences (all)	1	3	
Catarrh			
subjects affected / exposed	0 / 438 (0.00%)	3 / 440 (0.68%)	
occurrences (all)	0	3	
Sinus congestion			
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)	
occurrences (all)	0	0	
Cough			
subjects affected / exposed	8 / 438 (1.83%)	6 / 440 (1.36%)	
occurrences (all)	8	6	
Sneezing			
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)	
occurrences (all)	0	0	
Paranasal sinus discomfort			
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)	
occurrences (all)	0	0	
Rhinitis allergic			
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)	
occurrences (all)	0	0	
Asthma			

subjects affected / exposed occurrences (all)	1 / 438 (0.23%) 1	0 / 440 (0.00%) 0	
Throat irritation subjects affected / exposed occurrences (all)	1 / 438 (0.23%) 1	0 / 440 (0.00%) 0	
Pulmonary calcification subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1	
Aphonia subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	0 / 440 (0.00%) 0	
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	0 / 440 (0.00%) 0	
Bipolar disorder subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1	
Irritability subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1	
Investigations Smear cervix abnormal subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1	
Body temperature increased subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	0 / 440 (0.00%) 0	
Blood pressure decreased subjects affected / exposed occurrences (all)	1 / 438 (0.23%) 1	0 / 440 (0.00%) 0	
Injury, poisoning and procedural complications Fascial rupture subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1	
Limb injury			

subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)	
occurrences (all)	0	0	
Fall			
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)	
occurrences (all)	0	0	
Lip injury			
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)	
occurrences (all)	0	0	
Concussion			
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)	
occurrences (all)	1	0	
Patella fracture			
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)	
occurrences (all)	1	0	
Thermal burn			
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)	
occurrences (all)	1	0	
Animal bite			
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)	
occurrences (all)	0	1	
Arthropod bite			
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)	
occurrences (all)	0	1	
Muscle strain			
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)	
occurrences (all)	0	1	
Congenital, familial and genetic disorders			
Supernumerary teeth			
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)	
occurrences (all)	1	0	
Nervous system disorders			
Headache			
subjects affected / exposed	227 / 438 (51.83%)	196 / 440 (44.55%)	
occurrences (all)	247	209	
Migraine			

subjects affected / exposed	2 / 438 (0.46%)	3 / 440 (0.68%)	
occurrences (all)	2	3	
Dizziness			
subjects affected / exposed	2 / 438 (0.46%)	1 / 440 (0.23%)	
occurrences (all)	2	1	
Hypoaesthesia			
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)	
occurrences (all)	0	1	
Paraesthesia			
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)	
occurrences (all)	0	1	
Idiopathic intracranial hypertension			
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)	
occurrences (all)	0	0	
Syncope			
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)	
occurrences (all)	0	0	
Dizziness exertional			
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)	
occurrences (all)	1	0	
Blood and lymphatic system disorders			
Lymphadenopathy			
subjects affected / exposed	6 / 438 (1.37%)	4 / 440 (0.91%)	
occurrences (all)	6	4	
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	2 / 438 (0.46%)	1 / 440 (0.23%)	
occurrences (all)	2	1	
Vertigo positional			
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)	
occurrences (all)	0	0	
Excessive cerumen production			
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)	
occurrences (all)	0	0	
Ear pain			

subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	0 / 440 (0.00%) 0	
Eustachian tube disorder subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	0 / 440 (0.00%) 0	
External ear inflammation subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	0 / 440 (0.00%) 0	
Eye disorders			
Eye symptom subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	0 / 440 (0.00%) 0	
Blepharitis subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1	
Vision blurred subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1	
Eczema eyelids subjects affected / exposed occurrences (all)	1 / 438 (0.23%) 1	0 / 440 (0.00%) 0	
Gastrointestinal disorders			
Nausea subjects affected / exposed occurrences (all)	68 / 438 (15.53%) 72	54 / 440 (12.27%) 56	
Diarrhoea subjects affected / exposed occurrences (all)	59 / 438 (13.47%) 64	77 / 440 (17.50%) 77	
Abdominal pain subjects affected / exposed occurrences (all)	61 / 438 (13.93%) 61	63 / 440 (14.32%) 64	
Vomiting subjects affected / exposed occurrences (all)	9 / 438 (2.05%) 9	11 / 440 (2.50%) 11	
Flatulence			

subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)	
occurrences (all)	0	0	
Abdominal pain upper			
subjects affected / exposed	1 / 438 (0.23%)	1 / 440 (0.23%)	
occurrences (all)	1	1	
Gastritis			
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)	
occurrences (all)	1	0	
Constipation			
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)	
occurrences (all)	1	0	
Dyspepsia			
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)	
occurrences (all)	1	0	
Odynophagia			
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)	
occurrences (all)	1	0	
Diarrhoea haemorrhagic			
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)	
occurrences (all)	0	1	
Frequent bowel movements			
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)	
occurrences (all)	0	1	
Gastroesophageal reflux disease			
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)	
occurrences (all)	0	1	
Paraesthesia oral			
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)	
occurrences (all)	0	1	
Volvulus			
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)	
occurrences (all)	0	1	
Haemorrhoids thrombosed			
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)	
occurrences (all)	0	1	
Skin and subcutaneous tissue disorders			

Urticaria			
subjects affected / exposed	3 / 438 (0.68%)	1 / 440 (0.23%)	
occurrences (all)	3	1	
Rash			
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)	
occurrences (all)	0	0	
Pruritus			
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)	
occurrences (all)	0	0	
Erythema			
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)	
occurrences (all)	0	0	
Dermatitis atopic			
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)	
occurrences (all)	1	0	
Dermatitis			
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)	
occurrences (all)	0	1	
Rash macular			
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)	
occurrences (all)	0	1	
Rash pruritic			
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)	
occurrences (all)	0	1	
Renal and urinary disorders			
Bladder pain			
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)	
occurrences (all)	0	0	
Tubulointerstitial nephritis			
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)	
occurrences (all)	1	0	
Dysuria			
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)	
occurrences (all)	0	1	
Musculoskeletal and connective tissue disorders			

Myalgia		
subjects affected / exposed	4 / 438 (0.91%)	5 / 440 (1.14%)
occurrences (all)	4	5
Arthralgia		
subjects affected / exposed	3 / 438 (0.68%)	3 / 440 (0.68%)
occurrences (all)	3	3
Pain in extremity		
subjects affected / exposed	4 / 438 (0.91%)	2 / 440 (0.45%)
occurrences (all)	4	3
Neck pain		
subjects affected / exposed	2 / 438 (0.46%)	1 / 440 (0.23%)
occurrences (all)	2	1
Synovial cyst		
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)
occurrences (all)	0	1
Back pain		
subjects affected / exposed	3 / 438 (0.68%)	1 / 440 (0.23%)
occurrences (all)	3	1
Muscle contracture		
subjects affected / exposed	1 / 438 (0.23%)	2 / 440 (0.45%)
occurrences (all)	1	2
Torticollis		
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)
occurrences (all)	0	0
Groin pain		
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)
occurrences (all)	0	0
Musculoskeletal stiffness		
subjects affected / exposed	1 / 438 (0.23%)	1 / 440 (0.23%)
occurrences (all)	1	1
Axillary mass		
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)
occurrences (all)	1	0
Bone pain		
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)
occurrences (all)	1	0

Muscular weakness subjects affected / exposed occurrences (all)	1 / 438 (0.23%) 1	0 / 440 (0.00%) 0	
Arthritis subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1	
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1	
Pain in jaw subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1	
Tendonitis subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1	
Infections and infestations			
Pharyngitis subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	0 / 440 (0.00%) 0	
Nasopharyngitis subjects affected / exposed occurrences (all)	13 / 438 (2.97%) 13	15 / 440 (3.41%) 15	
Upper respiratory tract infection subjects affected / exposed occurrences (all)	8 / 438 (1.83%) 8	2 / 440 (0.45%) 3	
COVID-19 subjects affected / exposed occurrences (all)	7 / 438 (1.60%) 7	2 / 440 (0.45%) 2	
Urinary tract infection subjects affected / exposed occurrences (all)	3 / 438 (0.68%) 3	3 / 440 (0.68%) 3	
Sinusitis subjects affected / exposed occurrences (all)	1 / 438 (0.23%) 1	2 / 440 (0.45%) 2	
Influenza			

subjects affected / exposed	2 / 438 (0.46%)	0 / 440 (0.00%)
occurrences (all)	2	0
Bronchitis		
subjects affected / exposed	1 / 438 (0.23%)	3 / 440 (0.68%)
occurrences (all)	1	3
Pharyngotonsillitis		
subjects affected / exposed	0 / 438 (0.00%)	2 / 440 (0.45%)
occurrences (all)	0	2
Gastroenteritis viral		
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)
occurrences (all)	0	0
Respiratory tract infection		
subjects affected / exposed	1 / 438 (0.23%)	1 / 440 (0.23%)
occurrences (all)	1	1
Tonsillitis		
subjects affected / exposed	1 / 438 (0.23%)	1 / 440 (0.23%)
occurrences (all)	1	1
Nasal herpes		
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)
occurrences (all)	0	0
Cystitis		
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)
occurrences (all)	0	0
Eczema impetiginous		
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)
occurrences (all)	0	0
Laryngitis		
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)
occurrences (all)	0	0
Upper respiratory tract infection bacterial		
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)
occurrences (all)	0	0
Vulvovaginitis		
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)
occurrences (all)	0	0

Ear infection		
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)
occurrences (all)	0	0
Oral herpes		
subjects affected / exposed	0 / 438 (0.00%)	0 / 440 (0.00%)
occurrences (all)	0	0
Viral infection		
subjects affected / exposed	0 / 438 (0.00%)	1 / 440 (0.23%)
occurrences (all)	0	1
Pharyngitis streptococcal		
subjects affected / exposed	2 / 438 (0.46%)	0 / 440 (0.00%)
occurrences (all)	2	0
Conjunctivitis		
subjects affected / exposed	1 / 438 (0.23%)	1 / 440 (0.23%)
occurrences (all)	1	1
Gastroenteritis		
subjects affected / exposed	1 / 438 (0.23%)	1 / 440 (0.23%)
occurrences (all)	1	1
Viral upper respiratory tract infection		
subjects affected / exposed	1 / 438 (0.23%)	1 / 440 (0.23%)
occurrences (all)	1	1
Bacterial vulvovaginitis		
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)
occurrences (all)	1	0
Fungal infection		
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)
occurrences (all)	1	0
Gingivitis		
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)
occurrences (all)	1	0
Otitis media acute		
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)
occurrences (all)	1	0
Respiratory tract infection bacterial		
subjects affected / exposed	1 / 438 (0.23%)	0 / 440 (0.00%)
occurrences (all)	1	0

Suspected COVID-19 subjects affected / exposed occurrences (all)	1 / 438 (0.23%) 1	0 / 440 (0.00%) 0	
Bacterial vaginosis subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1	
Otitis externa subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1	
Pneumonia subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1	
Respiratory tract infection viral subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1	
Streptococcal infection subjects affected / exposed occurrences (all)	0 / 438 (0.00%) 0	1 / 440 (0.23%) 1	
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	1 / 438 (0.23%) 1	0 / 440 (0.00%) 0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
26 May 2022	<p>This protocol has been amended to reflect the following:</p> <ul style="list-style-type: none">• Primary and secondary objectives were modified to evaluate only 3 influenza strains (A/Tasmania/503/2020 (H3N2), B/Washington/02/2019, B/Phuket/3073/2013). The A/Victoria/2570/2019 (H1N1) was evaluated as part of the tertiary objectives.• The secondary safety objective and its corresponding endpoint related to assessment of safety of RSV maternal vaccine when given alone and co-administered with Flu D-QIV from vaccination up to study end was recategorized as a primary objective.• The interim analysis was removed following GSK's decision to stop enrollment and vaccination for active enrollment in all RSV MAT studies.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported